Biosimilars for Rheumatoid Arthritis: 5 Facts
New Biosimilars for Rheumatoid Arthritis
One of the hottest topics in rheumatology today is biosimilars to for rheumatoid arthritis (RA) and other immune mediated diseases. Dozens of biosimilar medicines are in various stages of development and several are already in use in Europe and Asia. Let’s look at five key questions patients are asking.
1) Are Biosimilars for Rheumatoid Arthritis the same as generics?
No. Generics are copies of brand-name drugs with the same active ingredient. According to the FDA, generics are bioequivalent, but the term biosimilar was coined to describe something else: “Biosimilars are highly similar to the reference product they were compared to, but have allowable differences because they are made from living organisms.”
2) Why are Biosimilars for Rheumatoid Arthritis not generics?
Biologics are made of large protein molecules that are derived from single cell lines. That’s actually the reason these medicines are given as injections and IV infusions, in case you ever wondered. The large molecules would be broken up by the digestive system if they were swallowed.
Biosimilars are created using a separate line of cells than the original biologic. They are carefully created so as to be highly similar to the originator. Biosimilars are expected to work similarly by the same mechanisms (such as TNF inhibition) as the reference products (biologics).
3) How are biosimilars tested and approved?
The biosimilar approval process includes demonstrating that the biosimilar is highly similar to the originator. There should be no “clinically meaningful differences” in terms of “safety, purity, and potency.” For biosimilars for rheumatoid arthritis treatment, clinical studies are done to demonstrate similarity in pharmacokinetics (how a drug effects the body), pharmacodynamics (mechanism of action of a drug), and immunogenicity (reactivity to the product).
You might also like to read:
- Are Biosimilars Justice in Competition for Biologics Like Enbrel?
- News on Biosimilar Biologics for Rheumatoid Arthritis / Rheumatoid Disease
4) Are Biosimilars for Rheumatoid Arthritis already FDA approved?
In 2016, the FDA has approved three biosimilars for rheumatoid arthritis treatment:
- Biosimilar to Remicade (infliximab): Inflectra
- Biosimilar to Humira (adalimumab): Amjevita
- Biosimilar to Enbrel (etanercept): Erelzi
They are not in use at this time, but their launch is soon expected in the US.
5) Are Biosimilars for Rheumatoid Arthritis cheaper?
As patents expire for originator biologics, biosimilars for rheumatoid arthritis have become available in several countries. Experts are estimating cost savings with biosimilars in the U.S. to be about 15% over originator biologics, but some say it could be as much as 35%.
A new biologic drug can take up to a decade and a billion dollars to develop, with extensive clinical trials. The biosimilar process is much shorter so it is less expensive to develop.
WHAT DO YOU THINK ABOUT BIOSIMILARS TO RHEUMATOID ARTHRITIS?
IF YOU RESPOND WELL TO YOUR CURRENT TREATMENT, WOULD YOU SWITCH TO A BIOSIMILAR?
- Triple Therapy / Combination Therapy for Rheumatoid Arthritis
- 21 Tips to Prepare for a Biologic Infusion
- Antibodies Lessen Effectiveness of Adalimumab / Humira
NOTE: Your comments are an important resource for future readers of this post in the months to come. Please find the comment link below each post.Kelly Young. All rights reserved.